HIV Infection of brain macrophages and microglia by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
BMC Proceedings
Open AccessOral presentation
HIV Infection of brain macrophages and microglia
Rebecca Dunfee, Elaine Thomas, Megan Mefford, Petronela Ancuta, 
Anupa Kamat, Kevin Kunstman, Steven Wolinsky and Dana Gabuzda*
Address: Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute and Department of Neurology, Harvard Medical School, 
Boston, MA, 02115, USA
Email: Dana Gabuzda* - dana_gabuzda@dfci.harvard.edu
* Corresponding author    
HIV infects brain macrophages and microglia, and causes
HIV-associated dementia (HAD) and milder forms of
neurocognitive impairment in 20–30% of patients who
develop AIDS. HIV entry into macrophages and microglia
is initiated by interaction between the envelope glycopro-
tein (Env) surface subunit gp120 and CD4, which induces
a conformational change in gp120 that exposes the co-
receptor binding site. The interaction of CD4-bound
gp120 with a co-receptor, usually CCR5 or CXCR4, trig-
gers conformational changes in gp120 and the transmem-
brane subunit gp41 that enable fusion and virus entry.
CCR5 is the primary co-receptor used for virus entry into
macrophages and microglia, but CCR5 usage is neither
necessary nor sufficient for macrophage tropism, suggest-
ing that determinants other than those that specify co-
receptor usage influence the capacity of HIV to enter mac-
rophages/microglia. Macrophages and microglia express
lower levels of CD4 on the cell surface than CD4+ T cells
in peripheral blood. By a combination of genetic, molec-
ular, and biochemical approaches, we identified specific
amino acid variants in the HIV envelope glycoproteins
that increase viral tropism for macrophages/microglia by
enhancing gp120-CD4 affinity (i.e., N283 in C2 region of
gp120) or exposure of the CD4 binding site (i.e., loss of
an N-linked glycan at 386 in V4 region of gp120). These
variants were more frequent in the brain of patients who
developed dementia compared to nondemented patients,
implying the importance of enhance HIV Env-CD4 inter-
actions for HIV neuropathogenesis in vivo. Elevated
plasma lipopolysaccharide (LPS), an indicator of micro-
bial translocation from a damaged leaky gut, is a likely
cause of systemic immune activation in chronic HIV infec-
tion. LPS induces monocyte activation and trafficking into
brain, which are key mechanisms in the pathogenesis of
HAD. To determine whether high LPS levels are associated
with increased monocyte activation and HAD, we
obtained peripheral blood samples from AIDS patients
and examined plasma LPS, peripheral blood monocytes,
and soluble markers of monocyte activation. Circulating
monocytes expressed high levels of the activation markers
CD69 and HLA-DR, and harbored low levels of HIV com-
pared to CD4+ T-cells. High plasma LPS levels were asso-
ciated with increased plasma sCD14 and LPS-binding
protein levels, and low endotoxin core antibody levels.
LPS levels were higher in HAD patients compared to con-
trol groups, and were associated with HAD independently
of plasma viral load and CD4 counts. These results pro-
vide a better understanding of mechanisms that underlie
neurotropism of HIV and suggest a role for elevated LPS
levels in driving monocyte activation and subsequent traf-
ficking of activated monocytes into the CNS, thereby pro-
moting neuroinflammation and increasing availability of
target cells permissive for HIV replication in brain.
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